Mr Jay Chatterjee is a Consultant Gynae-oncologist at the Royal Surrey County Hospital NHS Foundation Trust (Guildford) associated with the renowned St Luke's Cancer Centre. He is a sub-specialist in Gynaeoncology surgery, having done his fellowship at the prestigious West London Gynaeoncology Cancer center at the Hammersmith Hospital in London. He is also an honorary Clinical Senior Lecturer at Imperial College, London.
Jay completed his basic and intermediate training in Obstetrics and Gynaecology in and around London before being appointed to the North West Thames Deanery Obstetrics and Gynaecology program in 2006. He became a member of the Royal College of Obstetrics and Gynaecology in 2008. In October 2009, he deferred his clinical training in order to commence his academic PhD program at Imperial College, London (Division of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Hammersmith Hospital campus). His PhD focussed on an inhibitory T cell pathway, involved in dampening immune responses in ovarian Cancer. He has published extensively in his chosen field of specialization.
Mr. Chatterjee has been extensively involved in postgraduate education in the UK and is the course director of the extremely popular MRCOG Part 1 revision course at Imperial College, London. He has taught in various other courses and has been the editor of international best selling examination books. He was also a council member of the Royal College of Obstetricians and Gynaecologists (RCOG) and sat on numerous educational committees. He has written numerous chapters, books, and questions .He is also an invited course tutor for MRCOG Part1 & 2 courses held in India and Dubai. He has given numerous educational lectures nationally and internationally as an invited speaker.
Jay's research interest is in translational research, aimed at promoting new biomarker discovery and validation in gynaecological cancers. He has published on clinical interventations improving patient outcomes from gynaecological cancers. He is also part of the team involved in research in Human Uterine transplant in the UK. He is presently working to develop genomic, proteomic and immunomic characterization of tumours, so that novel therapies can be applied as part of personalized cancer care to improve survival from gynaecological cancers.
et al., Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry, International Journal of Molecular Medicine, ISSN:1107-3756
et al., 2018, The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers, Clinical Oncology, ISSN:0936-6555
et al., 2017, In-hospital clinical outcomes after upper gastrointestinal surgery: Data from an international observational study, Ejso, Vol:43, ISSN:0748-7983, Pages:2324-2332
et al., 2017, Use of failure-to-rescue to identify international variation in postoperative care in low-, middle- and high-income countries: a 7-day cohort study of elective surgery, British Journal of Anaesthesia, Vol:119, ISSN:0007-0912, Pages:258-266
et al., 2017, Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer, Clinical Cancer Research, Vol:23, ISSN:1078-0432, Pages:3453-3460